Advertisement
INCY vs RPRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and RPRX is a Hold.
INCY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INCY turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 23 of 35 cases over the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 59 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 207 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 61 cases where INCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
INCY moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
INCY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (2.788). P/E Ratio (14.717) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (440.869).
Aroon Indicator for RPRX shows an upward move is likely
RPRX's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 173 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.386) is normal, around the industry mean (2.788). P/E Ratio (35.989) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (133.911) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
INCY | RPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 27 | 15 | |
SMR RATING 1..100 | 33 | 97 | |
PRICE GROWTH RATING 1..100 | 28 | 36 | |
P/E GROWTH RATING 1..100 | 72 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RPRX's Valuation (91) in the Pharmaceuticals Major industry is in the same range as INCY (92) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.
RPRX's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is in the same range as INCY (27) in the Biotechnology industry. This means that RPRX’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that INCY’s stock grew somewhat faster than RPRX’s over the last 12 months.
INCY's Price Growth Rating (28) in the Biotechnology industry is in the same range as RPRX (36) in the Pharmaceuticals Major industry. This means that INCY’s stock grew similarly to RPRX’s over the last 12 months.
RPRX's P/E Growth Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (72) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than INCY’s over the last 12 months.
| INCY | RPRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 48% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 46% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 60% |
| Advances ODDS (%) | 10 days ago 63% | 2 days ago 55% |
| Declines ODDS (%) | 4 days ago 56% | 4 days ago 49% |
| BollingerBands ODDS (%) | 2 days ago 54% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 53% | 2 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 3 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s).
- INCY’s FA Score: 3 green, 2 red.
- RPRX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 6 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 6 bearish.
- RPRX’s TA Score: 6 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а -0.61% price change this week, while RPRX (@Biotechnology) price change was +2.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
INCY is expected to report earnings on Feb 09, 2027.
RPRX is expected to report earnings on Feb 16, 2027.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | +0.01% | ||
| AXON - RPRX | 48% Loosely correlated | -9.81% | ||
| INCY - RPRX | 47% Loosely correlated | -3.94% | ||
| VRTX - RPRX | 46% Loosely correlated | -1.19% | ||
| RIGL - RPRX | 40% Loosely correlated | -10.88% | ||
| EXEL - RPRX | 39% Loosely correlated | -5.55% | ||
More | ||||